CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Stifel 2016 Healthcare Conference, being held on November 15-16 in New York City.
|Stifel 2016 Healthcare Conference|
|Date:||Tuesday, November 15|
|Time:||2:15pm Eastern Time|
|Location:||The Lotte New York Palace Hotel, Holmes I Room|
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
Source:CoLucid Pharmaceuticals, Inc